Enfusion Retained Earnings vs Long Term Debt Analysis

ENFN Stock

USD 9.67 0.03 0.31%

Enfusion financial indicator trend analysis is much more than just examining Enfusion latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Enfusion is a good investment. Please check the relationship between Enfusion Retained Earnings and its Long Term Debt accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.

To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.

Retained Earnings vs Long Term Debt

Retained Earnings vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Enfusion Retained Earnings account and Long Term Debt. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Enfusion's Retained Earnings and Long Term Debt is -0.59. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Enfusion, assuming nothing else is changed. The correlation between historical values of Enfusion's Retained Earnings and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Enfusion are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Retained Earnings i.e., Enfusion's Retained Earnings and Long Term Debt go up and down completely randomly.

Correlation Coefficient

-0.59

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Long Term Debt

Long-term debt is a debt that Enfusion has held for over one year. Long-term debt appears on Enfusion balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Enfusion balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from Enfusion's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Enfusion current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.

To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.At this time, Enfusion's Selling General Administrative is very stable compared to the past year. As of the 18th of May 2024, Sales General And Administrative To Revenue is likely to grow to 0.46, while Tax Provision is likely to drop about 867 K.

	2021	2022	2023	2024 (projected)
Interest Expense	4.6M	413K	1.6M	2.0M
Depreciation And Amortization	2.8M	6.3M	8.6M	4.7M

Interest Expense Depreciation And Amortization

Enfusion fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital
Total Assets		-0.36	0.96	0.81	0.89	-0.55	0.89	0.89	-0.97	-0.81	-0.82	0.95	0.96	0.9	0.93	0.48	0.88	0.96	0.96	-0.51	-0.82	0.8	0.81	0.93	-0.8	0.95
Short Long Term Debt Total	-0.36		-0.42	-0.16	-0.69	-0.45	-0.67	-0.29	0.44	0.81	0.46	-0.43	-0.38	-0.3	-0.35	-0.26	0.07	-0.38	-0.31	0.33	0.79	-0.27	-0.19	-0.56	0.81	-0.57
Other Current Liab	0.96	-0.42		0.92	0.89	-0.49	0.89	0.96	-0.93	-0.77	-0.92	0.87	0.86	0.96	0.97	0.37	0.82	0.86	0.99	-0.3	-0.82	0.89	0.7	0.94	-0.8	0.93
Total Current Liabilities	0.81	-0.16	0.92		0.68	-0.61	0.7	0.97	-0.78	-0.47	-0.9	0.68	0.63	0.96	0.92	0.1	0.77	0.63	0.93	0.07	-0.6	0.93	0.55	0.8	-0.56	0.74
Total Stockholder Equity	0.89	-0.69	0.89	0.68		-0.31	1.0	0.8	-0.95	-0.95	-0.86	0.9	0.86	0.81	0.85	0.33	0.6	0.86	0.85	-0.45	-0.99	0.78	0.72	0.98	-0.98	0.99
Other Liab	-0.55	-0.45	-0.49	-0.61	-0.31		-0.35	-0.58	0.57	0.06	0.47	-0.49	-0.47	-0.58	-0.56	0.13	-0.73	-0.47	-0.6	-0.03	0.18	-0.64	-0.59	-0.47	0.14	-0.45
Net Tangible Assets	0.89	-0.67	0.89	0.7	1.0	-0.35		0.82	-0.96	-0.93	-0.88	0.9	0.85	0.83	0.87	0.28	0.6	0.85	0.86	-0.4	-0.98	0.81	0.73	0.98	-0.97	0.99
Property Plant And Equipment Net	0.89	-0.29	0.96	0.97	0.8	-0.58	0.82		-0.88	-0.62	-0.89	0.83	0.73	1.0	0.99	0.13	0.82	0.73	0.98	-0.07	-0.72	0.9	0.73	0.88	-0.69	0.85
Current Deferred Revenue	-0.97	0.44	-0.93	-0.78	-0.95	0.57	-0.96	-0.88		0.85	0.86	-0.96	-0.93	-0.89	-0.92	-0.32	-0.79	-0.93	-0.94	0.44	0.9	-0.84	-0.83	-0.97	0.88	-0.99
Net Debt	-0.81	0.81	-0.77	-0.47	-0.95	0.06	-0.93	-0.62	0.85		0.7	-0.84	-0.85	-0.63	-0.7	-0.53	-0.47	-0.85	-0.71	0.65	0.96	-0.57	-0.62	-0.87	0.97	-0.91
Retained Earnings	-0.82	0.46	-0.92	-0.9	-0.86	0.47	-0.88	-0.89	0.86	0.7		-0.71	-0.69	-0.89	-0.88	-0.13	-0.59	-0.69	-0.89	0.07	0.82	-0.98	-0.5	-0.94	0.79	-0.87
Accounts Payable	0.95	-0.43	0.87	0.68	0.9	-0.49	0.9	0.83	-0.96	-0.84	-0.71		0.93	0.84	0.9	0.37	0.83	0.93	0.89	-0.53	-0.85	0.68	0.93	0.89	-0.84	0.94
Cash	0.96	-0.38	0.86	0.63	0.86	-0.47	0.85	0.73	-0.93	-0.85	-0.69	0.93		0.75	0.8	0.63	0.82	1.0	0.86	-0.71	-0.8	0.65	0.78	0.86	-0.79	0.92
Non Current Assets Total	0.9	-0.3	0.96	0.96	0.81	-0.58	0.83	1.0	-0.89	-0.63	-0.89	0.84	0.75		0.99	0.14	0.83	0.75	0.98	-0.09	-0.74	0.9	0.74	0.89	-0.7	0.86
Non Currrent Assets Other	0.93	-0.35	0.97	0.92	0.85	-0.56	0.87	0.99	-0.92	-0.7	-0.88	0.9	0.8	0.99		0.19	0.84	0.8	0.98	-0.18	-0.78	0.88	0.8	0.91	-0.76	0.9
Other Assets	0.48	-0.26	0.37	0.1	0.33	0.13	0.28	0.13	-0.32	-0.53	-0.13	0.37	0.63	0.14	0.19		0.39	0.63	0.31	-0.86	-0.31	0.02	0.16	0.28	-0.32	0.36
Long Term Debt	0.88	0.07	0.82	0.77	0.6	-0.73	0.6	0.82	-0.79	-0.47	-0.59	0.83	0.82	0.83	0.84	0.39		0.82	0.88	-0.37	-0.48	0.64	0.83	0.68	-0.45	0.72
Cash And Short Term Investments	0.96	-0.38	0.86	0.63	0.86	-0.47	0.85	0.73	-0.93	-0.85	-0.69	0.93	1.0	0.75	0.8	0.63	0.82		0.86	-0.71	-0.8	0.65	0.78	0.86	-0.79	0.92
Net Receivables	0.96	-0.31	0.99	0.93	0.85	-0.6	0.86	0.98	-0.94	-0.71	-0.89	0.89	0.86	0.98	0.98	0.31	0.88	0.86		-0.27	-0.78	0.89	0.76	0.93	-0.75	0.91
Common Stock Shares Outstanding	-0.51	0.33	-0.3	0.07	-0.45	-0.03	-0.4	-0.07	0.44	0.65	0.07	-0.53	-0.71	-0.09	-0.18	-0.86	-0.37	-0.71	-0.27		0.45	0.03	-0.41	-0.35	0.47	-0.47
Non Current Liabilities Total	-0.82	0.79	-0.82	-0.6	-0.99	0.18	-0.98	-0.72	0.9	0.96	0.82	-0.85	-0.8	-0.74	-0.78	-0.31	-0.48	-0.8	-0.78	0.45		-0.72	-0.65	-0.94	1.0	-0.95
Inventory	0.8	-0.27	0.89	0.93	0.78	-0.64	0.81	0.9	-0.84	-0.57	-0.98	0.68	0.65	0.9	0.88	0.02	0.64	0.65	0.89	0.03	-0.72		0.53	0.89	-0.68	0.82
Other Current Assets	0.81	-0.19	0.7	0.55	0.72	-0.59	0.73	0.73	-0.83	-0.62	-0.5	0.93	0.78	0.74	0.8	0.16	0.83	0.78	0.76	-0.41	-0.65	0.53		0.71	-0.64	0.78
Other Stockholder Equity	0.93	-0.56	0.94	0.8	0.98	-0.47	0.98	0.88	-0.97	-0.87	-0.94	0.89	0.86	0.89	0.91	0.28	0.68	0.86	0.93	-0.35	-0.94	0.89	0.71		-0.92	0.99
Total Liab	-0.8	0.81	-0.8	-0.56	-0.98	0.14	-0.97	-0.69	0.88	0.97	0.79	-0.84	-0.79	-0.7	-0.76	-0.32	-0.45	-0.79	-0.75	0.47	1.0	-0.68	-0.64	-0.92		-0.94
Net Invested Capital	0.95	-0.57	0.93	0.74	0.99	-0.45	0.99	0.85	-0.99	-0.91	-0.87	0.94	0.92	0.86	0.9	0.36	0.72	0.92	0.91	-0.47	-0.95	0.82	0.78	0.99	-0.94

Click cells to compare fundamentals

Enfusion Account Relationship Matchups

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Enfusion offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enfusion's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enfusion Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enfusion Stock:

How To Invest In Enfusion

Details

Is Enfusion Stock a good investment?

Details

What is Enfusion's Net Worth?

Details

Largest Application Software Companies

View

Largest Software - Application Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enfusion. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.

To learn how to invest in Enfusion Stock, please use our How to Invest in Enfusion guide.

Note that the Enfusion information on this page should be used as a complementary analysis to other Enfusion's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.

Complementary Tools for Enfusion Stock analysis

When running Enfusion's price analysis, check to measure Enfusion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enfusion is operating at the current time. Most of Enfusion's value examination focuses on studying past and present price action to predict the probability of Enfusion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enfusion's price. Additionally, you may evaluate how the addition of Enfusion to your portfolios can decrease your overall portfolio volatility.

	Content Syndication Quickly integrate customizable finance content to your own investment portal
	Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
	Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas

Is Enfusion's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enfusion. If investors know Enfusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enfusion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.94)

Earnings Share

0.02

Revenue Per Share

2.055

Quarterly Revenue Growth

0.173

Return On Assets

0.0331

The market value of Enfusion is measured differently than its book value, which is the value of Enfusion that is recorded on the company's balance sheet. Investors also form their own opinion of Enfusion's value that differs from its market value or its book value, called intrinsic value, which is Enfusion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enfusion's market value can be influenced by many factors that don't directly affect Enfusion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Enfusion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Enfusion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enfusion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Enfusion Retained Earnings vs Long Term Debt Analysis

Retained Earnings vs Long Term Debt

Retained Earnings vs Long Term Debt Correlation Analysis

Correlation Coefficient

Retained Earnings

Long Term Debt

Enfusion fundamental ratios Correlations

Enfusion Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Enfusion Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Liab	+ 1.0	Non Current Liabilities Total
Net Receivables	+ 0.99	Other Current Liab
Net Invested Capital	+ 0.99	Total Stockholder Equity

Net Invested Capital	- 0.99	Current Deferred Revenue
Non Current Liabilities Total	- 0.99	Total Stockholder Equity
Inventory	- 0.98	Retained Earnings
Non Current Liabilities Total	- 0.98	Net Tangible Assets
Total Liab	- 0.98	Total Stockholder Equity
Other Stockholder Equity	- 0.97	Current Deferred Revenue